ProfileGDS5678 / 1429209_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 40% 36% 36% 36% 35% 33% 35% 35% 31% 35% 36% 35% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8532736
GSM967853U87-EV human glioblastoma xenograft - Control 22.9119840
GSM967854U87-EV human glioblastoma xenograft - Control 32.8109836
GSM967855U87-EV human glioblastoma xenograft - Control 42.7609736
GSM967856U87-EV human glioblastoma xenograft - Control 52.7713836
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.886235
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8148333
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7880135
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7832435
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6960331
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7960635
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7831236
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8001935
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7753734